| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Anti-HIV Agents | 16 | 2018 | 2209 | 1.38 | Why? |
| HIV Infections | 41 | 2020 | 11620 | 1.35 | Why? |
| HIV-1 | 25 | 2018 | 3365 | 1.05 | Why? |
| HIV Protease Inhibitors | 5 | 2018 | 434 | 1.03 | Why? |
| Cobicistat | 2 | 2018 | 172 | 0.82 | Why? |
| Darunavir | 4 | 2018 | 477 | 0.75 | Why? |
| Tablets | 1 | 2018 | 219 | 0.69 | Why? |
| Pyridazines | 1 | 2018 | 86 | 0.68 | Why? |
| Schistosomiasis haematobia | 1 | 2017 | 45 | 0.67 | Why? |
| Antiretroviral Therapy, Highly Active | 7 | 2018 | 952 | 0.54 | Why? |
| Drug Resistance, Viral | 7 | 2018 | 1083 | 0.50 | Why? |
| Reverse Transcriptase Inhibitors | 3 | 2018 | 309 | 0.46 | Why? |
| gag Gene Products, Human Immunodeficiency Virus | 3 | 2018 | 95 | 0.46 | Why? |
| Pneumocystis carinii | 1 | 2013 | 205 | 0.43 | Why? |
| CD4-Positive T-Lymphocytes | 8 | 2018 | 4545 | 0.36 | Why? |
| Emigrants and Immigrants | 1 | 2017 | 888 | 0.36 | Why? |
| Pneumonia, Pneumocystis | 1 | 2013 | 322 | 0.36 | Why? |
| Adenosine Deaminase | 2 | 2018 | 85 | 0.34 | Why? |
| HIV Envelope Protein gp41 | 3 | 2017 | 153 | 0.33 | Why? |
| Residence Characteristics | 1 | 2017 | 1927 | 0.32 | Why? |
| Nevirapine | 1 | 2005 | 57 | 0.29 | Why? |
| Pyrimidinones | 1 | 2005 | 76 | 0.28 | Why? |
| Anti-Retroviral Agents | 6 | 2018 | 1099 | 0.28 | Why? |
| Aging | 2 | 2018 | 3581 | 0.28 | Why? |
| HIV Protease | 2 | 2017 | 86 | 0.26 | Why? |
| CD4 Lymphocyte Count | 6 | 2018 | 1517 | 0.26 | Why? |
| HIV Envelope Protein gp120 | 2 | 2018 | 267 | 0.25 | Why? |
| Mass Behavior | 1 | 2021 | 68 | 0.23 | Why? |
| Cytomegalovirus Infections | 2 | 2017 | 667 | 0.21 | Why? |
| Viral Load | 13 | 2021 | 15850 | 0.21 | Why? |
| Drug Therapy, Combination | 9 | 2018 | 7268 | 0.21 | Why? |
| Virus Replication | 9 | 2021 | 14331 | 0.21 | Why? |
| RNA-Binding Proteins | 2 | 2018 | 1022 | 0.21 | Why? |
| Raltegravir Potassium | 2 | 2018 | 132 | 0.20 | Why? |
| Lymphocyte Activation | 3 | 2018 | 2742 | 0.20 | Why? |
| Hepatitis C | 4 | 2018 | 1514 | 0.19 | Why? |
| Endosperm | 1 | 2018 | 5 | 0.19 | Why? |
| Music | 1 | 2021 | 107 | 0.19 | Why? |
| Host-Pathogen Interactions | 5 | 2021 | 11041 | 0.19 | Why? |
| Squamous Intraepithelial Lesions of the Cervix | 1 | 2018 | 21 | 0.19 | Why? |
| Cytochrome P-450 CYP3A Inducers | 1 | 2018 | 9 | 0.19 | Why? |
| Virus Latency | 2 | 2018 | 251 | 0.19 | Why? |
| Anus Neoplasms | 1 | 2020 | 123 | 0.18 | Why? |
| Immunoglobulins, Intravenous | 2 | 2021 | 2705 | 0.18 | Why? |
| Electrosurgery | 1 | 2018 | 35 | 0.18 | Why? |
| Plants, Genetically Modified | 1 | 2018 | 84 | 0.18 | Why? |
| Condylomata Acuminata | 1 | 2018 | 62 | 0.18 | Why? |
| Rivastigmine | 1 | 2017 | 6 | 0.18 | Why? |
| Acitretin | 1 | 2017 | 23 | 0.18 | Why? |
| Anus Diseases | 1 | 2018 | 55 | 0.18 | Why? |
| Cardiomyopathy, Hypertrophic | 1 | 2020 | 193 | 0.18 | Why? |
| SAM Domain and HD Domain-Containing Protein 1 | 1 | 2017 | 20 | 0.17 | Why? |
| Oryza | 1 | 2018 | 86 | 0.17 | Why? |
| Immune Reconstitution | 1 | 2017 | 48 | 0.17 | Why? |
| Cervical Intraepithelial Neoplasia | 1 | 2018 | 114 | 0.17 | Why? |
| Emtricitabine | 1 | 2018 | 202 | 0.17 | Why? |
| RNA Editing | 1 | 2017 | 80 | 0.17 | Why? |
| Lamivudine | 1 | 2018 | 210 | 0.16 | Why? |
| Membrane Lipids | 1 | 2017 | 91 | 0.16 | Why? |
| Cognitive Dysfunction | 2 | 2019 | 1389 | 0.16 | Why? |
| Neuropsychological Tests | 2 | 2019 | 954 | 0.16 | Why? |
| Acquired Immunodeficiency Syndrome | 3 | 2017 | 533 | 0.16 | Why? |
| Spain | 9 | 2021 | 15545 | 0.15 | Why? |
| Viremia | 3 | 2018 | 1020 | 0.15 | Why? |
| Hepacivirus | 3 | 2018 | 1509 | 0.15 | Why? |
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 275 | 0.15 | Why? |
| Genes, env | 1 | 2014 | 17 | 0.15 | Why? |
| Adenine | 1 | 2018 | 463 | 0.15 | Why? |
| Adult | 37 | 2021 | 244371 | 0.15 | Why? |
| HIV Antibodies | 2 | 2018 | 776 | 0.15 | Why? |
| Immunity, Innate | 3 | 2018 | 6570 | 0.15 | Why? |
| Elasticity Imaging Techniques | 1 | 2017 | 194 | 0.14 | Why? |
| Neuroprotective Agents | 1 | 2017 | 240 | 0.14 | Why? |
| Receptors, IgG | 1 | 2018 | 578 | 0.14 | Why? |
| Tenofovir | 1 | 2018 | 449 | 0.14 | Why? |
| Maintenance Chemotherapy | 1 | 2014 | 133 | 0.14 | Why? |
| Selection, Genetic | 2 | 2017 | 691 | 0.14 | Why? |
| Antibodies, Neutralizing | 5 | 2021 | 25288 | 0.13 | Why? |
| Pyrrolidinones | 1 | 2013 | 66 | 0.13 | Why? |
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2013 | 39 | 0.13 | Why? |
| T-Lymphocytes, Cytotoxic | 1 | 2018 | 552 | 0.13 | Why? |
| HIV Integrase | 1 | 2013 | 67 | 0.13 | Why? |
| Sulfonamides | 2 | 2014 | 1294 | 0.13 | Why? |
| Male | 37 | 2021 | 367725 | 0.13 | Why? |
| Cognition Disorders | 1 | 2019 | 574 | 0.13 | Why? |
| Hydroxychloroquine | 3 | 2021 | 12447 | 0.12 | Why? |
| Sarcopenia | 1 | 2018 | 422 | 0.12 | Why? |
| Nitriles | 1 | 2018 | 1053 | 0.12 | Why? |
| Osteoporosis | 1 | 2018 | 410 | 0.12 | Why? |
| Humans | 66 | 2021 | 930598 | 0.12 | Why? |
| Dysbiosis | 1 | 2018 | 685 | 0.12 | Why? |
| Codon | 1 | 2013 | 287 | 0.12 | Why? |
| Female | 35 | 2021 | 380317 | 0.12 | Why? |
| HIV | 2 | 2018 | 1116 | 0.12 | Why? |
| RNA, Viral | 12 | 2020 | 32276 | 0.12 | Why? |
| Antiviral Agents | 4 | 2020 | 41703 | 0.12 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2021 | 1138 | 0.11 | Why? |
| Middle Aged | 28 | 2021 | 270681 | 0.11 | Why? |
| Protease Inhibitors | 2 | 2007 | 3630 | 0.11 | Why? |
| Salvage Therapy | 1 | 2013 | 417 | 0.11 | Why? |
| Eosinophils | 1 | 2017 | 848 | 0.11 | Why? |
| Evolution, Molecular | 3 | 2017 | 3691 | 0.11 | Why? |
| Neutralization Tests | 2 | 2021 | 6698 | 0.11 | Why? |
| Swine Diseases | 1 | 2020 | 1219 | 0.11 | Why? |
| Lymphocyte Subsets | 1 | 2018 | 987 | 0.11 | Why? |
| Intestinal Mucosa | 1 | 2018 | 1046 | 0.10 | Why? |
| Demography | 1 | 2017 | 1660 | 0.10 | Why? |
| Feasibility Studies | 1 | 2020 | 3467 | 0.10 | Why? |
| Sexual and Gender Minorities | 1 | 2020 | 1019 | 0.10 | Why? |
| Uterine Cervical Neoplasms | 1 | 2018 | 842 | 0.10 | Why? |
| Pyrimidines | 1 | 2018 | 1557 | 0.10 | Why? |
| Cytopathogenic Effect, Viral | 1 | 2012 | 635 | 0.10 | Why? |
| Ritonavir | 1 | 2005 | 4212 | 0.10 | Why? |
| Immunity, Humoral | 5 | 2021 | 4849 | 0.09 | Why? |
| Developed Countries | 1 | 2013 | 500 | 0.09 | Why? |
| Anti-Infective Agents | 1 | 2020 | 1766 | 0.09 | Why? |
| Adjuvants, Immunologic | 1 | 2018 | 1709 | 0.09 | Why? |
| Viral Tropism | 1 | 2017 | 1329 | 0.09 | Why? |
| Treatment Failure | 4 | 2020 | 2106 | 0.09 | Why? |
| Epitopes | 2 | 2020 | 4113 | 0.09 | Why? |
| Absorptiometry, Photon | 2 | 2018 | 168 | 0.09 | Why? |
| Drug Costs | 1 | 2011 | 313 | 0.09 | Why? |
| Hepatitis C, Chronic | 1 | 2017 | 973 | 0.09 | Why? |
| Membrane Fusion | 1 | 2012 | 713 | 0.09 | Why? |
| Leukocyte Count | 1 | 2017 | 3178 | 0.08 | Why? |
| Platelet Aggregation Inhibitors | 1 | 2018 | 1671 | 0.08 | Why? |
| Patient Compliance | 4 | 2020 | 1468 | 0.08 | Why? |
| Kidney Diseases | 1 | 2018 | 1434 | 0.08 | Why? |
| Gene Knockdown Techniques | 2 | 2017 | 347 | 0.08 | Why? |
| Antibodies, Viral | 6 | 2021 | 51949 | 0.08 | Why? |
| Carbamates | 1 | 2010 | 485 | 0.08 | Why? |
| Oligopeptides | 1 | 2010 | 576 | 0.08 | Why? |
| HIV-Associated Lipodystrophy Syndrome | 1 | 2005 | 15 | 0.07 | Why? |
| Immunoglobulin M | 2 | 2020 | 9091 | 0.07 | Why? |
| Immunologic Memory | 1 | 2018 | 3362 | 0.07 | Why? |
| Liver Cirrhosis | 1 | 2017 | 1810 | 0.07 | Why? |
| Macrophages | 1 | 2017 | 2784 | 0.07 | Why? |
| HLA-DR Antigens | 2 | 2018 | 563 | 0.07 | Why? |
| HIV Fusion Inhibitors | 1 | 2005 | 80 | 0.07 | Why? |
| Polyethylene Glycols | 1 | 2010 | 574 | 0.07 | Why? |
| Drug Tolerance | 1 | 2005 | 100 | 0.07 | Why? |
| Genetic Techniques | 1 | 2004 | 79 | 0.07 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 2426 | 0.07 | Why? |
| ADP-ribosyl Cyclase 1 | 2 | 2017 | 96 | 0.07 | Why? |
| Carrier Proteins | 1 | 2007 | 513 | 0.07 | Why? |
| CD4 Antigens | 2 | 2018 | 306 | 0.07 | Why? |
| Immunization, Passive | 1 | 2020 | 10067 | 0.07 | Why? |
| Chronic Disease | 2 | 2017 | 5139 | 0.07 | Why? |
| Renal Insufficiency, Chronic | 1 | 2018 | 2654 | 0.07 | Why? |
| Antibodies, Monoclonal | 3 | 2018 | 8041 | 0.07 | Why? |
| Interferon-alpha | 2 | 2010 | 1442 | 0.07 | Why? |
| Pyridines | 1 | 2010 | 680 | 0.07 | Why? |
| Genotype | 4 | 2018 | 4697 | 0.06 | Why? |
| Cohort Studies | 4 | 2021 | 36005 | 0.06 | Why? |
| Genetic Predisposition to Disease | 1 | 2018 | 4027 | 0.06 | Why? |
| Coronary Artery Disease | 1 | 2018 | 2570 | 0.06 | Why? |
| Coinfection | 3 | 2017 | 6820 | 0.06 | Why? |
| B-Lymphocytes | 1 | 2018 | 4418 | 0.06 | Why? |
| Ribavirin | 1 | 2010 | 1182 | 0.06 | Why? |
| T-Lymphocyte Subsets | 1 | 2010 | 1387 | 0.06 | Why? |
| Prospective Studies | 6 | 2021 | 43301 | 0.06 | Why? |
| Cholesterol, HDL | 1 | 2005 | 439 | 0.06 | Why? |
| Immunologic Factors | 1 | 2017 | 4206 | 0.05 | Why? |
| Cholesterol, LDL | 1 | 2005 | 499 | 0.05 | Why? |
| Prevalence | 4 | 2018 | 25773 | 0.05 | Why? |
| Cell Line | 4 | 2021 | 12040 | 0.05 | Why? |
| Alanine | 1 | 2018 | 5687 | 0.05 | Why? |
| Homosexuality, Male | 2 | 2020 | 1158 | 0.05 | Why? |
| RNA, Messenger | 1 | 2014 | 5131 | 0.05 | Why? |
| Transplantation Chimera | 1 | 2018 | 17 | 0.05 | Why? |
| Antigens, Viral | 3 | 2021 | 6298 | 0.05 | Why? |
| Bacteroides | 1 | 2018 | 16 | 0.05 | Why? |
| Human papillomavirus 6 | 1 | 2018 | 8 | 0.05 | Why? |
| Survival Analysis | 1 | 2013 | 7592 | 0.05 | Why? |
| Human papillomavirus 11 | 1 | 2018 | 12 | 0.05 | Why? |
| Phytohemagglutinins | 1 | 2018 | 15 | 0.05 | Why? |
| Diagnostic Tests, Routine | 2 | 2021 | 2643 | 0.05 | Why? |
| Molecular Sequence Data | 3 | 2013 | 3198 | 0.05 | Why? |
| Archaea | 1 | 2018 | 30 | 0.05 | Why? |
| Butyrates | 1 | 2018 | 31 | 0.05 | Why? |
| CD28 Antigens | 1 | 2018 | 39 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.05 | Why? |
| Ionomycin | 1 | 2017 | 11 | 0.05 | Why? |
| Tetradecanoylphorbol Acetate | 1 | 2017 | 23 | 0.05 | Why? |
| Proviruses | 1 | 2018 | 82 | 0.05 | Why? |
| Pilot Projects | 3 | 2018 | 5182 | 0.04 | Why? |
| Virus Integration | 1 | 2018 | 96 | 0.04 | Why? |
| Cytochrome P-450 CYP3A | 1 | 2018 | 88 | 0.04 | Why? |
| Recurrence | 2 | 2018 | 3675 | 0.04 | Why? |
| Treatment Outcome | 7 | 2021 | 51732 | 0.04 | Why? |
| Antigens, Differentiation, T-Lymphocyte | 1 | 2018 | 146 | 0.04 | Why? |
| Silver | 1 | 2021 | 327 | 0.04 | Why? |
| Infrared Rays | 1 | 2018 | 127 | 0.04 | Why? |
| Lipids | 1 | 2005 | 1079 | 0.04 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.04 | Why? |
| Mitochondria | 1 | 2005 | 857 | 0.04 | Why? |
| Adoptive Transfer | 1 | 2018 | 250 | 0.04 | Why? |
| CD3 Complex | 1 | 2018 | 237 | 0.04 | Why? |
| Zidovudine | 1 | 2017 | 63 | 0.04 | Why? |
| Hand Strength | 1 | 2018 | 202 | 0.04 | Why? |
| Interleukin-7 | 1 | 2018 | 148 | 0.04 | Why? |
| DEAD-box RNA Helicases | 1 | 2017 | 99 | 0.04 | Why? |
| Administration, Intravenous | 1 | 2021 | 1115 | 0.04 | Why? |
| Lopinavir | 2 | 2018 | 4308 | 0.04 | Why? |
| Lithium | 1 | 2017 | 56 | 0.04 | Why? |
| Cost-Benefit Analysis | 2 | 2021 | 2259 | 0.04 | Why? |
| Gene Expression | 2 | 2018 | 3332 | 0.04 | Why? |
| Benchmarking | 1 | 2021 | 627 | 0.04 | Why? |
| DNA Replication | 1 | 2017 | 121 | 0.04 | Why? |
| Administration, Cutaneous | 1 | 2017 | 229 | 0.04 | Why? |
| Primary Cell Culture | 1 | 2018 | 501 | 0.04 | Why? |
| Inflammation | 4 | 2021 | 13255 | 0.04 | Why? |
| HIV-2 | 1 | 2017 | 92 | 0.04 | Why? |
| Safety | 1 | 2005 | 1583 | 0.04 | Why? |
| Oxazines | 1 | 2018 | 279 | 0.04 | Why? |
| Aged | 8 | 2021 | 215776 | 0.04 | Why? |
| HIV Integrase Inhibitors | 1 | 2018 | 173 | 0.04 | Why? |
| Antibody-Dependent Cell Cytotoxicity | 1 | 2018 | 349 | 0.04 | Why? |
| Comorbidity | 2 | 2018 | 34796 | 0.04 | Why? |
| Interleukin-2 | 1 | 2018 | 443 | 0.04 | Why? |
| Retrospective Studies | 6 | 2020 | 105322 | 0.04 | Why? |
| Case-Control Studies | 3 | 2021 | 17671 | 0.04 | Why? |
| Incidental Findings | 1 | 2020 | 487 | 0.04 | Why? |
| Mass Screening | 3 | 2021 | 8005 | 0.04 | Why? |
| Sequence Analysis, DNA | 3 | 2013 | 2830 | 0.04 | Why? |
| HIV Seropositivity | 1 | 2018 | 320 | 0.04 | Why? |
| Capsid | 1 | 2017 | 197 | 0.04 | Why? |
| Proof of Concept Study | 1 | 2018 | 696 | 0.04 | Why? |
| Immunoglobulins | 1 | 2021 | 811 | 0.04 | Why? |
| Protein Stability | 1 | 2018 | 756 | 0.04 | Why? |
| Tetanus Toxoid | 1 | 2017 | 136 | 0.04 | Why? |
| Animals | 6 | 2021 | 78931 | 0.04 | Why? |
| Cysteine Endopeptidases | 1 | 2004 | 1557 | 0.04 | Why? |
| Executive Function | 1 | 2017 | 173 | 0.04 | Why? |
| Transplantation, Homologous | 1 | 2018 | 757 | 0.04 | Why? |
| rev Gene Products, Human Immunodeficiency Virus | 1 | 2014 | 4 | 0.04 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.04 | Why? |
| Cell Death | 1 | 2018 | 536 | 0.04 | Why? |
| Models, Animal | 1 | 2018 | 788 | 0.04 | Why? |
| Bone Density | 1 | 2018 | 335 | 0.04 | Why? |
| Drug Interactions | 2 | 2018 | 1653 | 0.04 | Why? |
| DEAD Box Protein 58 | 1 | 2017 | 250 | 0.04 | Why? |
| Macrophage Activation | 1 | 2017 | 315 | 0.04 | Why? |
| Lectins, C-Type | 1 | 2018 | 405 | 0.04 | Why? |
| Protein Engineering | 1 | 2018 | 536 | 0.04 | Why? |
| Follow-Up Studies | 3 | 2018 | 17020 | 0.04 | Why? |
| Piperazines | 1 | 2018 | 445 | 0.04 | Why? |
| Chemokines | 1 | 2021 | 1095 | 0.04 | Why? |
| Peptide Fragments | 1 | 2005 | 2075 | 0.04 | Why? |
| Cells, Cultured | 2 | 2018 | 5835 | 0.03 | Why? |
| Cross-Sectional Studies | 5 | 2021 | 53120 | 0.03 | Why? |
| Sensitivity and Specificity | 3 | 2021 | 22971 | 0.03 | Why? |
| Risk-Taking | 1 | 2018 | 508 | 0.03 | Why? |
| Immunohistochemistry | 1 | 2021 | 2275 | 0.03 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.03 | Why? |
| Plasma | 2 | 2014 | 1809 | 0.03 | Why? |
| Cricetinae | 1 | 2021 | 3344 | 0.03 | Why? |
| Ventilation | 1 | 2021 | 1145 | 0.03 | Why? |
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 502 | 0.03 | Why? |
| Cats | 1 | 2020 | 1890 | 0.03 | Why? |
| Reverse Transcription | 1 | 2017 | 673 | 0.03 | Why? |
| Africa South of the Sahara | 1 | 2018 | 1335 | 0.03 | Why? |
| Spleen | 1 | 2018 | 877 | 0.03 | Why? |
| Gene Editing | 1 | 2017 | 330 | 0.03 | Why? |
| Receptors, Immunologic | 1 | 2017 | 555 | 0.03 | Why? |
| Phosphorylation | 1 | 2017 | 1060 | 0.03 | Why? |
| Cardiovascular Diseases | 1 | 2018 | 11497 | 0.03 | Why? |
| Cell Culture Techniques | 1 | 2018 | 704 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2021 | 11304 | 0.03 | Why? |
| Disease Models, Animal | 2 | 2021 | 10998 | 0.03 | Why? |
| Antigens, CD | 1 | 2018 | 984 | 0.03 | Why? |
| Pyridones | 1 | 2018 | 738 | 0.03 | Why? |
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2017 | 624 | 0.03 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.03 | Why? |
| RNA Stability | 1 | 2013 | 285 | 0.03 | Why? |
| Cytomegalovirus | 1 | 2017 | 600 | 0.03 | Why? |
| Receptors, CXCR4 | 1 | 2012 | 83 | 0.03 | Why? |
| Viral Regulatory and Accessory Proteins | 1 | 2017 | 482 | 0.03 | Why? |
| Hematologic Diseases | 1 | 2018 | 614 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.03 | Why? |
| Swine | 1 | 2020 | 3352 | 0.03 | Why? |
| Risk Factors | 3 | 2018 | 71621 | 0.03 | Why? |
| Muscle, Skeletal | 1 | 2018 | 915 | 0.03 | Why? |
| Mutation | 3 | 2018 | 12376 | 0.03 | Why? |
| Dose-Response Relationship, Drug | 1 | 2020 | 3776 | 0.03 | Why? |
| HEK293 Cells | 2 | 2017 | 8394 | 0.03 | Why? |
| DNA Mutational Analysis | 1 | 2013 | 581 | 0.03 | Why? |
| Polymorphism, Genetic | 1 | 2018 | 1074 | 0.03 | Why? |
| Fatal Outcome | 1 | 2020 | 3438 | 0.03 | Why? |
| Signal Transduction | 2 | 2017 | 7207 | 0.03 | Why? |
| Stents | 1 | 2018 | 916 | 0.03 | Why? |
| Structure-Activity Relationship | 1 | 2017 | 2219 | 0.03 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.03 | Why? |
| Cell Fusion | 1 | 2012 | 400 | 0.03 | Why? |
| Cell Proliferation | 1 | 2018 | 1973 | 0.03 | Why? |
| Amino Acid Substitution | 1 | 2017 | 1706 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.03 | Why? |
| Drug Administration Schedule | 2 | 2010 | 2324 | 0.02 | Why? |
| Viral Nonstructural Proteins | 1 | 2007 | 4810 | 0.02 | Why? |
| Papillomavirus Infections | 1 | 2018 | 861 | 0.02 | Why? |
| Decision Trees | 1 | 2011 | 441 | 0.02 | Why? |
| Immunity | 1 | 2021 | 2651 | 0.02 | Why? |
| Europe | 2 | 2018 | 12702 | 0.02 | Why? |
| Cross Reactions | 1 | 2021 | 4374 | 0.02 | Why? |
| Double-Blind Method | 1 | 2020 | 5988 | 0.02 | Why? |
| Flow Cytometry | 1 | 2018 | 2393 | 0.02 | Why? |
| Furans | 1 | 2010 | 156 | 0.02 | Why? |
| Viral Matrix Proteins | 1 | 2017 | 1243 | 0.02 | Why? |
| Adaptive Immunity | 1 | 2021 | 2585 | 0.02 | Why? |
| Viral Proteins | 1 | 2007 | 7370 | 0.02 | Why? |
| Medication Adherence | 1 | 2018 | 1270 | 0.02 | Why? |
| Antimalarials | 1 | 2021 | 2505 | 0.02 | Why? |
| Primary Health Care | 1 | 2007 | 4839 | 0.02 | Why? |
| Early Detection of Cancer | 1 | 2020 | 1956 | 0.02 | Why? |
| HeLa Cells | 1 | 2012 | 1303 | 0.02 | Why? |
| Fluorescent Dyes | 1 | 2012 | 536 | 0.02 | Why? |
| DNA, Viral | 1 | 2018 | 2521 | 0.02 | Why? |
| Mice | 2 | 2018 | 21357 | 0.02 | Why? |
| Atazanavir Sulfate | 1 | 2010 | 213 | 0.02 | Why? |
| Expert Testimony | 1 | 2011 | 658 | 0.02 | Why? |
| Incidence | 2 | 2021 | 25622 | 0.02 | Why? |
| Protein Domains | 1 | 2020 | 6563 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2020 | 4002 | 0.02 | Why? |
| Age Factors | 2 | 2018 | 21039 | 0.02 | Why? |
| Phylogeny | 2 | 2017 | 13341 | 0.02 | Why? |
| CD8-Positive T-Lymphocytes | 2 | 2017 | 5837 | 0.02 | Why? |
| Genetic Variation | 2 | 2013 | 3919 | 0.02 | Why? |
| Odds Ratio | 1 | 2018 | 5861 | 0.02 | Why? |
| Luminescent Measurements | 1 | 2012 | 924 | 0.02 | Why? |
| Self Report | 1 | 2019 | 3802 | 0.02 | Why? |
| Disease Progression | 3 | 2017 | 13580 | 0.02 | Why? |
| Protein Conformation | 1 | 2017 | 4386 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2017 | 5542 | 0.02 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.02 | Why? |
| Bacteriophage lambda | 1 | 2004 | 6 | 0.02 | Why? |
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 334 | 0.02 | Why? |
| Immunoglobulin G | 2 | 2021 | 21571 | 0.02 | Why? |
| Body Mass Index | 1 | 2018 | 4306 | 0.02 | Why? |
| Lymphatic Diseases | 1 | 2005 | 96 | 0.02 | Why? |
| Gastrointestinal Microbiome | 1 | 2018 | 1961 | 0.02 | Why? |
| Immunity, Cellular | 1 | 2018 | 3614 | 0.02 | Why? |
| Feces | 1 | 2018 | 4235 | 0.02 | Why? |
| Peptides | 1 | 2017 | 2513 | 0.02 | Why? |
| Amino Acid Sequence | 2 | 2007 | 6049 | 0.02 | Why? |
| Interferon Type I | 1 | 2017 | 2789 | 0.02 | Why? |
| Protein Binding | 1 | 2020 | 11430 | 0.02 | Why? |
| Leukocytes, Mononuclear | 1 | 2013 | 2115 | 0.02 | Why? |
| Models, Molecular | 1 | 2017 | 7616 | 0.02 | Why? |
| CD4-CD8 Ratio | 1 | 2003 | 235 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2018 | 9893 | 0.02 | Why? |
| Recombination, Genetic | 1 | 2010 | 1265 | 0.02 | Why? |
| Liver | 1 | 2017 | 4007 | 0.02 | Why? |
| Pandemics | 2 | 2020 | 389249 | 0.01 | Why? |
| Nausea | 1 | 2005 | 457 | 0.01 | Why? |
| Asymptomatic Infections | 1 | 2021 | 7218 | 0.01 | Why? |
| Virus Internalization | 1 | 2020 | 7921 | 0.01 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.01 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 1261 | 0.01 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.01 | Why? |
| Immunogenicity, Vaccine | 1 | 2017 | 4624 | 0.01 | Why? |
| Sequence Alignment | 1 | 2007 | 2109 | 0.01 | Why? |
| Contact Tracing | 1 | 2021 | 8448 | 0.01 | Why? |
| Percutaneous Coronary Intervention | 1 | 2018 | 3646 | 0.01 | Why? |
| Sex Factors | 1 | 2018 | 11014 | 0.01 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.01 | Why? |
| SARS Virus | 1 | 2004 | 13021 | 0.01 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2004 | 12361 | 0.01 | Why? |
| Virus Diseases | 1 | 2017 | 3779 | 0.01 | Why? |
| Recombinant Proteins | 1 | 2010 | 3786 | 0.01 | Why? |
| Adolescent | 2 | 2021 | 86841 | 0.01 | Why? |
| Cytokines | 1 | 2021 | 15010 | 0.01 | Why? |
| Masks | 1 | 2021 | 8528 | 0.01 | Why? |
| Phenotype | 1 | 2010 | 4037 | 0.01 | Why? |
| Biomarkers | 1 | 2021 | 23361 | 0.01 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.01 | Why? |
| Prognosis | 1 | 2018 | 32490 | 0.01 | Why? |
| Fatigue | 1 | 2005 | 2479 | 0.01 | Why? |
| Risk Assessment | 1 | 2018 | 25439 | 0.01 | Why? |
| Diarrhea | 1 | 2005 | 2743 | 0.01 | Why? |
| Models, Theoretical | 1 | 2011 | 6659 | 0.01 | Why? |
| Models, Biological | 1 | 2009 | 4907 | 0.01 | Why? |
| Acute Disease | 1 | 2004 | 6029 | 0.01 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.01 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2004 | 5164 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2011 | 15421 | 0.01 | Why? |
| Pneumonia | 1 | 2005 | 5652 | 0.00 | Why? |
| Pregnancy | 1 | 2004 | 23879 | 0.00 | Why? |
| Quality of Life | 1 | 2003 | 9820 | 0.00 | Why? |